CAMX.ST Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 17:29):

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...

Stats
Tagesvolumen	58 907.00
Durchschnittsvolumen	114 644
Marktkapitalisierung	28.24B
EPS	SEK0 ( 2024-02-14 )
Nächstes Ertragsdatum	( SEK0.990 ) 2024-05-07
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	65.33
ATR14	SEK0.412 (0.08%)

Volumen Korrelation

Lang: -0.17 (neutral)

Kurz: -0.30 (neutral)

Signal:(63.388) Neutral

Camurus AB (publ) Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Camurus AB (publ) Korrelation - Währung/Rohstoff

-0.47
( neutral )

-0.44
( neutral )

-0.84
( strong negative )

0.20
( neutral )

0.25
( neutral )

0.73
( moderate )

Camurus AB (publ) Finanzdaten

Annual	2023
Umsatz:	SEK1.72B
Bruttogewinn:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2023
Umsatz:	SEK1.72B
Bruttogewinn:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2022
Umsatz:	SEK956.34M
Bruttogewinn:	SEK853.08M (89.20 %)
EPS:	SEK1.010

FY	2021
Umsatz:	SEK600.57M
Bruttogewinn:	SEK515.22M (85.79 %)
EPS:	SEK-1.660

Financial Reports:

No articles found.

Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.